U.S. Markets close in 4 hrs 33 mins
  • S&P 500

    4,482.53
    +11.16 (+0.25%)
     
  • Dow 30

    35,317.88
    +23.12 (+0.07%)
     
  • Nasdaq

    14,947.32
    +49.98 (+0.34%)
     
  • Russell 2000

    2,264.84
    -0.82 (-0.04%)
     
  • Gold

    1,768.50
    +0.20 (+0.01%)
     
  • EUR/USD

    1.1608
    +0.0007 (+0.0580%)
     
  • 10-Yr Bond

    1.5950
    +0.0760 (+5.00%)
     
  • Vix

    16.66
    +0.36 (+2.21%)
     
  • GBP/USD

    1.3714
    +0.0038 (+0.2743%)
     
  • USD/JPY

    114.2850
    +0.6080 (+0.5349%)
     
  • BTC-USD

    61,770.32
    +890.56 (+1.46%)
     
  • CMC Crypto 200

    1,438.35
    -13.29 (-0.92%)
     
  • FTSE 100

    7,203.88
    -30.15 (-0.42%)
     
  • Nikkei 225

    29,025.46
    +474.56 (+1.66%)
     

Kiniksa Pharmaceuticals to Present at 39th Annual J.P. Morgan Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

HAMILTON, Bermuda, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021 at 4:30 p.m. Eastern Time.

A live webcast of Kiniksa’s presentation will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. A replay of the webcast will be available on Kiniksa’s website for 14 days following the conference.

About Kiniksa
Kiniksa is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa’s product candidates, rilonacept, mavrilimumab, vixarelimab and KPL-404, are based on strong biologic rationale or validated mechanisms, target underserved conditions and offer the potential for differentiation. These pipeline assets are designed to modulate immunological pathways across a spectrum of diseases. For more information, please visit www.kiniksa.com.

Every Second Counts!™

Kiniksa Investor and Media Contact
Mark Ragosa
(781) 430-8289
mragosa@kiniksa.com